Sudden blastic transformation (SBT) has been reported in 0.5% to 2.5% of patients treated with interferon-alpha during the first three years of therapy. Imatinib (IM) is now standard therapy for patients with chronic myeloid leukemia in chronic phase. We investigated the occurrence of SBT among patients treated with IM. Among 541 patients treated with IM in chronic phase, 23 developed blast phase, which was of sudden onset (i.e., occurring in patients previously in complete cytogenetic remission) in 4 patients (17%; 0.7% of the total), 2 lymphoid and 2 myeloid. Patients with SBT were found to have more often low-risk features at the time of presentation and had achieved optimal response with IM.
Introduction
Philadelphia chromosome (Ph)-positive chronic myeloid leukemia has a bi-or tri-phasic clinical course that includes chronic, accelerated, and blastic phases. 1 Imatinib is first-line therapy for CML, with 80% to 90% achieving a complete cytogenetic response (CGCR) and 60% to 70% a major molecular response. 2, 3 Patients that do not respond to therapy will ultimately progress to blast phase, usually going through the accelerated phase or a poorly controlled chronic phase. 4 Sudden blastic transformation (SBT) (i.e., blastic transformation occurring unexpectedly in patients in complete hematologic remission -CHR-) has been reported after IFN-therapy at a rate of 0.5% to 2.5% in the first 3 years. 5 There is a little information on the occurrence of SBT among patients treated with imatinib. Two isolated instances of SBT have been reported among patients in CGCR after imatinib therapy. 6, 7 Herein we report four patients who developed SBT after being in CGCR achieved with imatinib. This is the first series to report the frequency and clinical characteristics of SBT after imatinib.
Materials and methods
All 541 patients with Ph-positive CML in chronic phase treated with imatinib at MD Anderson Cancer Center since 1999 were reviewed. Approval was obtained from the M.D.
Anderson Cancer Center institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki. Patients were followed with CBC every 6-8 weeks and bone marrow aspiration and cytogenetic analysis every 3 months for the first 12 months and then every 6 months. A CHR was defined as a white blood cell count of <10x10 9 /L with normal differential, platelet count <450x10 9 /L, and no splenomegaly lasting for at least 4
weeks. CHR was further categorized by the best cytogenetic response: CGCR, Ph-positive 0%;
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Blastic-phase CML was defined by the presence of 30% peripheral or bone marrow blasts or presence of extramedullary disease, and categorized as lymphoid or myeloid by immunohistochemistry and flow cytometry. 4 A sudden onset of blastic-phase CML was defined as having its onset after a documented CGCR in the immediately preceding bone marrow analysis and within 3 months of a normal CBC.
Results and Discussion
After a median follow-up of 46 months (range, 7-54), 23 of the 541 patients analyzed 
Patient 4:
A 58-year-old man with CML CP started therapy with imatinib 800 mg daily.
He achieved a CGCR after 3 months and was sustained for 22 months. The best BCR-ABL/ABL ratio achieved was 0.8656% and rose progressively to 9.837% (still in CGCR). He then SBT was reported at a rate of 2.2% in patients in CHR after IFN-. 5 SBT occurring in patients in CGCR has been reported rarely [6] [7] [8] , including 2 patients following treatment with imatinib. 6, 7 SBT as defined in this report occurred in 4 of 145 (2.7%) patients in CGCR after IFN-therapy (3 lymphoid, 1 undifferentiated). 5 SBT has also been reported in 5 patients after SCT 9 , and, interestingly, one of our patients had a second SBT after SCT. These instances could suggest the selection of an aggressive sub-clone of Ph-positive cells with a proliferative advantage over the normal hematopoietic cells. It was reported that primitive Ph-positive cells may be insensitive to imatinib and persist despite an apparent optimal clinical response. 10, 11 Combination therapies may be required to eliminate these early progenitors and prevent emergence of resistant clones.
Although achieving a MMR is associated with improved progression-free survival, 2,12 2 patients in this series had an SBT after achieving a MMR. The 2 other patients did not achieve a MMR and were having an increase in BCR-ABL transcript levels before the SBT. Interestingly, we found no mutations in abl kinase domain, while all 4 patients developed clonal evolution at the time of transformation. Clonal evolution was also identified at the time of SBT in the one patient previously reported evaluable for cytogenetics 7 , and one of the two previously reported patients was assessed for mutations and none was identified. 6 Thus, the mechanism of resistance in these patients may be less dependent on abl kinase mutations than among patients with a more "gradual" failure to imatinib.
Finally, the two patients with SBT after imatinib previously reported and most of those reported after IFN-had lymphoid phenotype, 6, 7 while two of our patients had a myeloid phenotype. Interestingly, all had abnormalities in chromosome 8 at the time of transformation.
To investigate whether these abnormalities may have been present before the time of SBT, we did FISH for chromosome 8 in the bone marrow immediately preceding the transformation in 3 patients with analyzable samples. None had abnormal signals for chromosome 8.
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